Polycystic Ovary SyndromeLife Extension Suggestions
Polycystic Ovary Syndrome
A woman who finds herself with irregular menstrual cycles, excess facial and body hair, adult acne, weight gain, infertility and enlarged ovaries may have polycystic ovary syndrome (PCOS), an unfortunate condition that afflicts 5-10 percent of women of childbearing age and approximately 70-90 percent of women with irregular menstrual cycles (Azziz et al 2004). Among its many symptoms, PCOS causes hormonal imbalances, including elevated testosterone (male hormone) and estrogen (female hormone) levels, as well as increased insulin levels (Azziz 2006, Moran 2010).
Although PCOS is the most common female endocrine disorder in the United States, its cause remains unclear (McCartney 2004). Perhaps this is why “syndrome” is most commonly used in conventional medicine to describe PCOS since the word itself alludes to its varied signs and symptoms but does not indicate a precise cause of the condition.
However, research largely overlooked by mainstream medicine reveals a strong association between PCOS, obesity, and insulin resistance, including characteristic features of insulin insensitivity such as dyslipidemia (abnormality of metabolism of fats) and hypertension (Diamanti-Kandarakis 2007, Sasaki 2011).
If left untreated, women with PCOS often develop severe clinical manifestations, such as hirsutism (excess facial and body hair), adult acne, infertility, and depression (Diamanti-Kandarakis 2008, Drosdzol 2007). Women with PCOS are at significantly higher risk for developing cardiovascular disease (Teede 2010) and endometrial cancer (Chittenden et al 2009).
Integrative medicine recognizes the seriousness of PCOS, as well as the need to approach the management of PCOS as a disease of insulin resistance in order to offer hope to the millions of women who suffer from this disease. For example, metformin, an insulin sensitizing agent that also helps to reduce excessive androgen production, promotes weight loss, restores fertility, and enhances glucose metabolism in patients with PCOS, is drastically underutilized by conventional medicine for this disease. However, management strategies commonly used to control individual symptoms of PCOS are known to have a number of undesirable side effects (Pasquali 2011).
Fortunately, for the millions suffering with PCOS published clinical studies support the use of natural therapeutics, such as inositol and N-acetyl-cysteine (NAC), for controlling the symptoms and side effects.
Symptoms of PCOS
One of the challenging aspects of diagnosing PCOS is that the signs and symptoms vary from person to person, in both type and severity. Frequently, PCOS symptoms are mistaken for other medical illnesses. However, common symptoms include:
Menstrual abnormality is the most widespread characteristic of PCOS. These include cycles longer than 35 days (fewer than eight menstrual cycles a year); failure to menstruate for four months or longer; and prolonged periods that may be scant or heavy (Ma 2010).
Excess androgen production: Increased androgen levels are a key feature of PCOS, and may result in excess facial and body hair (hirsutism), adult acne and male-pattern baldness (in women). Worth noting, however, is that the physical signs of androgen excess vary with ethnicity. As an example, the prevalence of hirsutism in PCOS patients is at least 40% in European and American females, yet is even more common in darker skin types, but women of Asian descent may not be affected (Lowenstein 2006).
Polycystic ovaries: Enlarged ovaries containing numerous small cysts can be detected by ultrasound. However, some women with polycystic ovaries may not have PCOS, while some women with the condition have ovaries that appear normal (Azziz 2004).
Other conditions associated with PCOS
Infertility: PCOS is the most common cause of female infertility. Many women with polycystic ovary syndrome experience infrequent ovulation or lack of ovulation altogether and may have trouble becoming pregnant. PCOS also is associated with spontaneous abortion and preeclampsia (van der Spuy 2004).
Obesity: Compared with women of similar age who don't have polycystic ovary syndrome, women with PCOS are significantly more likely to be overweight or obese (Martínez-Bermejo 2007, Moran 2010). Furthermore, about half of all women with PCOS manifest central obesity, in which there is a greater deposition of visceral fat around internal organs in the abdominal region, as opposed to the fat being located on the thighs and hips. Abdominal fat distribution is associated with increased risk of hypertension, diabetes and lipid abnormalities (Faloia 2004).
Insulin resistance and type 2 diabetes: Studies have found that women with PCOS have higher incidences of insulin resistance and type 2 diabetes than age and weight-matched controls (Moran 2010). Moreover, a majority of obese PCOS women and more than half of those of normal weight are insulin resistant (Pasquali 2006), and a significant number develop type 2 diabetes mellitus by the age of 40 (Pelusi 2004).
Acanthosis nigricans is a dark, poorly defined, velvety hyperpigmentation found on the nape of the neck, armpits, inner thighs, vulva, or under the breasts. This condition is a sign of insulin resistance, which leads to higher circulating insulin levels. Insulin spillover into the skin results in hyperplasia, an abnormal increase in skin growth (Higgins 2008).
Diagnosis of PCOS
There is no specific test to definitively diagnose polycystic ovary syndrome. The diagnosis is one of exclusion, which means the doctor considers all signs and symptoms to rule out other possible disorders (Azziz 2004). A standard diagnostic assessment for PCOS includes a full medical history, at which time a doctor will consider irregular or absent periods, obesity, hirsutism (coarse facial and body hair), and poor breast development. During a physical exam, doctors typically look for physical signs of PCOS like acne, facial hair, male pattern baldness and acanthosis nigricans.
A pelvic or transvaginal ultrasound is used to detect "follicular arrest", or the development of small (5–7mm) follicles that never reach the preovulatory size of 16 mm or more. Though not all women with PCOS have polycystic ovaries (PCO), nor do all women with ovarian cysts have PCOS (Artini 2010), ultrasonographic scanning has substantially broadened the phenotypic spectrum of PCOS (Azziz 2004).
Diagnostic criteria published by the Androgen Excess Society in 2006 require the presence of clinical or biochemical hyperandrogenism, with either menstrual dysfunction or polycystic ovarian morphology (PCOM), which are detected via transvaginal ultrasonography (Artini 2010).
Blood work is used to measure the levels of several hormones and to exclude the many possible causes of menstrual abnormalities or androgen excess that mimic PCOS. Along with tests used to measure elevated androgen levels, doctors may look for high levels of luteinizing hormones (LH) or an elevation in the ratio of LH to follicle stimulating hormone (FSH), prolactin, thyroid stimulating hormone (TSH), 17-hydroxyprogesterone, testosterone and DHEA-S. Other associated conditions such as high levels of glucose, insulin, cholesterol and triglycerides, as well as insulin resistance may also be assessed (Shi 2007).
Some doctors now screen for high levels of anti-Müllerian Hormone (AMH) since it is considered a potential diagnostic marker for PCOS (Chen 2008, Dewailly 2010). AMH is a protein released by cells that are involved with the growth of the egg follicle. AMH levels correlate with the number of antral follicles (small follicles that are 2 to 8 mm in size and appear in the beginning of the menstrual cycle) found on the ovary; the higher the antral follicle count, the higher the AMH levels (van Houten 2010). Women with PCOS typically have a high number of antral follicles; they have correspondingly high AMH levels as well (Pellatt 2010).
Causes and risk factors for PCOS
PCOS was once regarded solely as a reproductive disorder affecting women of childbearing age. Anovulation (a menstrual cycle in which ovulation does not occur) and androgen excess have been considered the hallmark diagnostic criteria of the syndrome (Azziz 2004). However, insulin resistance is now identified as a significant contributor to the pathogenesis of PCOS, the metabolic and cardiovascular consequences of which are widely acknowledged within the scientific community (Pasquali 2011). To date, several factors involved in the development of PCOS have been identified:
LH Secretion and Androgen Excess: Past research has emphasized the role of neuroendocrine abnormalities in the persistent and excessive secretion of luteinizing hormones (LH), one of two glycoprotein hormones that stimulate the final ripening of the follicles and the secretion of progesterone. Excessive LH triggers premature ovulation, disrupting the follicle’s maturation process and leading to an increase in androgen production by ovarian theca cells. Some research points to increased LH as the driving force for PCOS in slender and normal body-weight women (Chang 2000).
Hyperinsulinemia and Androgen Excess: Hyperinsulinemia produces hyperandrogenism in women with PCOS via two distinct and independent mechanisms. The first is the stimulation of ovarian androgen production. Studies have shown that insulin acts synergistically with LH to enhance androgen production in ovarian theca cells (Guzick 2004, Tsilchorozidou 2004). The second is by directly and independently reducing serum sex hormone-binding globulin (SHBG) levels.
Genetics and Androgen Excess: An increase in LH, as well as hyperinsulinemia, leads to an increase in androgen production by ovarian theca cells (Tsilchorozidou 2004). Research indicates that morphological changes in the ovaries, including ovarian cyst development and theca-cell (steroid-producing cells in the ovaries) dysfunction, may be an indication of a genetic basis for PCOS. Researchers suspect there is a genetically determined ovarian defect present in women with PCOS, causing the ovary to overproduce androgen (Tsilchorozidou, 2004, Jakubowski 2005, Diamanti-Kandarakis 2006, Bremer 2008). Indeed, abnormal theca cell activity seems to be a primary source for excess androgens (Wood 2003).
The following risk factors are also thought to have a strong influence over the progression of PCOS.
Obesity. Studies have found that obesity not only contributes to the development of PCOS, but arises also as a result (Martínez-Bermejo 2007). The adipose tissue of women with PCOS is characterized by enlarged fat cells (hypertrophic adipocytes) and impairments in the body’s ability to break down fat (lipolysis) and regulate insulin. Whether these abnormalities are primary or secondary to hyperandrogenism or other PCOS-related abnormalities is not yet known (Villa 2011).
Age at onset. Some research suggests that girls who develop pubic hair early (often before the age of eight, a condition known as premature pubarche) have many of the signs and symptoms of PCOS. In one study that followed prepubescent girls throughout puberty, premature pubarche resulted in excess testosterone production and irregular periods consistent with PCOS, leading researchers to conclude that premature pubarche may be an early form of PCOS (Witchel 2006).
Other risk factors that may play a role in the pathogenesis of PCOS include chronic inflammation (Escobar-Morreale 2011); exposure to endocrine-disrupting chemicals (Takeuchi 2004); autoimmune disorders, especially those involving the ovaries, pancreas, thyroid and adrenal glands (Petríková 2010); and the use of medications that increase prolactin production (Hernández 2000).
Laying aside etiology, women with PCOS are prone to defects in insulin signaling, which aggravates the synthesis of androgens in the ovaries and adrenal gland (Tsilchorozidou 2004). Excess androgens encourage insulin resistance, leading to elevated insulin levels, which in turn stimulate further androgen synthesis. This vicious cycle results in a “snowball effect” worsening PCOS symptoms and making sufferers especially susceptible to obesity and diabetes, conditions that significantly compound the syndrome’s progression (Schuring 2008, Pasquali 2011).
Conventional treatment of PCOS
Polycystic ovary syndrome treatment generally focuses on management of the individual main concerns, such as infertility, hirsutism, acne or obesity.
Infertility:Ovulation induction remains a milestone in the treatment of women with anovulatory infertility (Polyzos 2009).
Regulation of the menstrual cycle:
Long term PCOS management:
Side Effects with Conventional Treatments
A pitfall of mainstream approaches to PCOS is that they are often associated with unwanted side effects, for example: